

DAFTAR PUSTAKA

1. Widjanarko A, Sudoyo AW, Salonder H. Anemia Aplastik. In: Buku Ajar Ilmu Penyakit Dalam. Jilid VII. Jakarta: Interna Publishing; 2024. p.3178-87.
2. Nimmana BK, Penney SW. Aplastic Anemia. [Updated 2025 Jul 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534212>
3. Ahmed P, Chaudhry Q, et al. Epidemiology of aplastic anemia: a study of 1324 cases. Hematology. 2020;25(1):48-54. doi:10.1080/16078454.2019.1711344
4. Rizki A, Rofinda D. Profil Penderita Anemia Aplastik di RSUP Dr. M. Djamil Padang Tahun 2018-2019. Indones J Health Sci. 2021;2(1). Available from: <https://jikesi.fk.unand.ac.id>
5. Moore CA, Krishnan K. Aplastic Anemia. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534212>
6. Al-Ghazaly J, Al-Dubai W, Al-Jahafi AK, et al. Cyclosporine monotherapy for severe aplastic anemia: a developing country experience. Ann Saudi Med. 2015;25(5):375-9.
7. Mandal PK, Baul S, Dolai TK, De R, Chakrabarti P. Outcome of cyclosporine monotherapy in patients of aplastic anemia: experience of a tertiary care hospital in Eastern India. Indian J Hematol Blood Transfus. 2017;33(1):144-7. doi:10.1007/s12288-016-0706-7
8. Matsuda K, Koya J, Arai S, Nakazaki K, Nakamura F, Kurokawa M. Cyclosporine therapy in patients with transfusion-independent non-severe aplastic anemia: a retrospective analysis. Intern Med. 2019;58(3):355-60. doi:10.2169/internalmedicine.1372-18
9. Li H, Fu L, Yang B, Chen H, Ma J, Wu R. Cyclosporine monotherapy in patients with non-severe aplastic anemia: a retrospective analysis. Front Med (Lausanne). 2022;9:805197. doi:10.3389/fmed.2022.805197
10. Awan MN, Shahbaz N, Hidayat I, Kerio AA, Khan H, Siddiq A. Response to single agent cyclosporin in patients with non-severe aplastic anaemia. J Coll Physicians Surg Pak. 2024;34(9):1056-60. doi:10.29271/jcpsp.2024.09.1056
11. Ghazanfar M, Khan S, et al. Frequency of cure with cyclosporin therapy in patients with aplastic anemia. Biomedica. 2014;30(4):258-62. (DOI tidak tersedia)
12. Wang J, Shen P, Wu X, Jin W. Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: a meta-analysis of retrospective studies. Exp Ther Med. 2020;19(4):3104-12. doi:10.3892/etm.2020.8536
13. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol. 2024;204(3):784-804. doi:10.1111/bjh.19236
14. Somprasertkul T, Trirattanapikul W, et al. Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia. Med Drug Discov. 2024;22:100181. doi:10.1016/j.medidd.2024.100181
15. Antonio MR, Iacobelli S, Kulasekararaj AG, et al. Eltrombopag added to standard immunosuppressive treatment improves long-term outcomes as front-line therapy for severe aplastic anemia: final 2-year analysis of EBMT-SAAWP RACE study. Blood. 2024;144(Suppl 1):302. doi:10.1182/blood-2024-194699
16. Nakamura R, Patel BA, Kim S, Wong FL, Armenian SH, Groarke EM, et al. Conditional survival and standardized mortality ratios of patients with severe

- aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy. *Haematologica*. 2023;108(12):3298-307. doi:10.3324/haematol.2023.282781
17. Leyu W, Ye L, Zhao X, Chen M, Zhang F, Han B. Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study. *Blood Cancer J*. 2025;15(1):119. doi:10.1038/s41408-025-01328-3
 18. Julen K, Volken T, Holbro A, et al. Transfusions in aplastic anemia patients cause HLA alloimmunization: comparisons of current and past cohorts demonstrate progress. *Transplant Cell Ther*. 2021;27(11):939.e1-939.e8. doi:10.1016/j.jtct.2021.07.017
 19. Yawen Z, Yao H, Suli W, et al. Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic. *Front Immunol*. 2023;14:1197982. doi:10.3389/fimmu.2023.1197982
 20. Piekarska A, Pawelec K, Szmigielska-Kapłon A, Ussowicz M. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. *Front Immunol*. 2024;15:1378432. doi:10.3389/fimmu.2024.1378432
 21. Wirk B. Acquired aplastic anemia therapies: immunosuppressive therapy versus alternative donor hematopoietic cell transplantation. *J Hematol*. 2024;13(3):61-70. doi:10.14740/jh1264
 22. Young NS. Aplastic anemia. *N Engl J Med*. 2018;379(17):1643-56. doi:10.1056/NEJMra1413485
 23. Prabahran A, Durrani J, Coelho-Da Silva J, Shalhoub R, Lotter J, Rios O, et al. Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. *Br J Haematol*. 2024;205(3):1170-9. doi:10.1111/bjh.19648
 24. Li J, Xue C, Liu G, Gao G, Wei D. Factors influencing bloodstream infections after immunosuppressive therapy in patients with aplastic anemia: a logistic regression analysis. *Am J Transl Res*. 2024;16(10):5667-75. doi:10.62347/URKZ2878
 25. Bacigalupo A. How I treat acquired aplastic anemia. *Blood*. 2017;129(11):1428-36. doi:10.1182/blood-2016-08-693481
 26. Chapman J, Zhang Y. Histology, Hematopoiesis. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534246>
 27. Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts. *Eur J Haematol*. 2018;101(6):711-20. doi:10.1111/ejh.13153
 28. Solomou EE. Idiopathic aplastic anemia: an update. *Clin Hematol Int*. 2019;1(1):52. doi:10.2991/chi.d.190321.002
 29. Ruan J, Han B. Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A. *Chin Med J (Engl)*. 2021;134(19):2356-8. doi:10.1097/CM9.0000000000001365
 30. Scheinberg P. Progress in medical therapy in aplastic anemia: why it took so long? *Int J Hematol*. 2024;119(3):248-54. doi:10.1007/s12185-024-03713-3
 31. Peslak SA, Olson T, Babushok DV. Diagnosis and treatment of aplastic anemia. *Curr Treat Options Oncol*. 2017;18(12):71. doi:10.1007/s11864-017-0511-z
 32. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. *Blood Adv*. 2021;5(12):2660-71. doi:10.1182/bloodadvances.2021004345

33. Flores C, Fouquet G, et al. Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications. *Front Immunol.* 2019;10:588. doi:10.3389/fimmu.2019.00588
34. World Health Organization Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000. Available from: <http://iris.wpro.who.int/handle/10665.1/5379> (iris.wpro.who.int in Bing)
35. Scheinberg P, Brummendorf T, Latour R, et al. Incidence, time to diagnosis, and therapeutic landscape of aplastic anemia: results from a large United States claims database. *Blood.* 2024;144(Suppl 1):2329. doi:10.1182/blood-2024-204908
36. Patel B, Townsley D, Scheinberg P. Immunosuppressive therapy in severe aplastic anemia. *Semin Hematol.* 2022;59(1):21-9. doi:10.1053/j.seminhematol.2022.01.002
37. Walter J, Rolles B, Schumacher Y, et al. Analysis of the impact of body mass index (BMI) on the durability of response in patients with aplastic anemia treated with weight-adjusted horse anti-thymocyte globulin (hATG). *Blood.* 2023;142(Suppl 1):5641. doi:10.1182/blood-2023-183075
38. Yu J, Wei X, Gao J, et al. Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity. *Toxicol.* 2023;492:153544. doi:10.1016/j.tox.2023.153544
39. Fadini GP, Albiero M. Impaired haematopoietic stem/progenitor cell traffic and multi-organ damage in diabetes. *Stem Cells.* 2022;40: sxac035. doi:10.1093/stmcls/sxac035
40. Liu J, Lu XY, Cheng L, Yang Y, Lin SY, Yin H, et al. Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with absolute neutrophil count of zero. *Hematology.* 2019;24(1):492-7. doi:10.1080/16078454.2019.1631424
41. Groarke EM, Durrani J, Chen LN, Shalhoub RN, Baez V, Glass J, et al. Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy. *Blood Adv.* 2025;9(11):2639-50. doi:10.1182/bloodadvances.2024015301